Trials / Completed
CompletedNCT04500535
A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment (LIST, Lung Initiative on Sequence Therapy)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 535 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: * The characteristics and treatment sequence of patients treated with nivolumab * The effectiveness of nivolumab treatment * The safety profile of nivolumab * Treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab * The patient-reported outcomes (PRO) in patients treated with nivolumab, at baseline and during follow up using the EuroQoL-5D-3L
Conditions
Timeline
- Start date
- 2020-09-28
- Primary completion
- 2025-04-18
- Completion
- 2025-04-18
- First posted
- 2020-08-05
- Last updated
- 2025-11-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04500535. Inclusion in this directory is not an endorsement.